

This is a repository copy of Reducing inappropriate polypharmacy through a patient-centred, shared decision-making model of deprescribing.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/119551/

Version: Accepted Version

Proceedings Paper:

Marques, I, Petty, D, Raynor, T et al. (1 more author) (2017) Reducing inappropriate polypharmacy through a patient-centred, shared decision-making model of deprescribing. In: Pharmacoepidemiology and Drug Safety. PRIMM: Prescribing and Research in Medicines Management (UK & Ireland) Annual Conference 2017, 28 Jan 2017, University of Coventry London Campus. Wiley , pp. 12-13.

https://doi.org/10.1002/pds.4221

© 2017, The Authors. Parmacoepidemiology and Drug Safety © 2017 John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Marques, I, Petty, D, Raynor, T et al. (1 more author) (2017) Reducing inappropriate polypharmacy through a patient-centred, shared decision-making model of deprescribing. In: Pharmacoepidemiology and Drug Safety. PRIMM: Prescribing and Research in Medicines Management (UK & Ireland) Annual Conference 2017, 28 Jan 2017, University of Coventry London Campus. Wiley , pp. 12-13., which has been published in final form at https://doi.org/10.1002/pds.4221. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



REDUCING INAPPROPRIATE POLYPHARMACY THROUGH A PATIENT-CENTRED, SHARED DECISION-MAKING MODEL OF DEPRESCRIBING

Marques, I.a, Petty, D.a, Raynor, T.b, Blenkinsopp, A.a

On behalf of the Bradford-Leeds Medicines Minimisation Research Team

Introduction: Medicines are a core intervention in the NHS, costing over £15 billion every year (HSCIC, 2014). Notwithstanding their potential to improve patients' health, avoidable harm from inappropriate polypharmacy is recurrent, posing risk to health and increasing financial pressures on the NHS.

Barriers and enablers of deprescribing were recently identified (Reeve et al., 2013, Luymes et al., 2016) along with the need to make deprescribing consultations patient-centred. However, current models of deprescribing remain untested, and practice and outcomes vary. Additionally, no studies have been conducted with frail elderly patients, who may benefit from deprescribing the most. A multidisciplinary team was brought together to review existing literature, identifying the need for designing an evidence-based, patient-centred deprescribing process capable of identifying and reducing inappropriate medicines to increase patients' health and reduce NHS costs.

Aim: To design a patient-centred, shared decision-making model of deprescribing.

Methods: Empirical evidence will inform the design of the new model of deprescribing by identifying why, what and how to deprescribe. Primary care electronic health record data from a cohort of elderly patients with frailty (n=250) will be analysed quantitatively to discern associations between medicines, frailty and health decline. Additionally, qualitative interviews with primary care prescribers (i.e. general practitioners, nurses and pharmacists, n=20) and patients experienced and naïve to deprescribing (n=25) will investigate perceptions, expectations and experiences of deprescribing.

Discussion: Quantitative findings will inform which common medicines pose greater risk to frail patients and are suitable for deprescribing (why and what to deprescribe). Qualitative findings will inform the design of the deprescribing model. Patients' and prescribers' views and experiences will highlight behaviours and resources required to an effective patient-centred, shared decision-making deprescribing consultation blueprint (how to deprescribe).

Conclusion: This will be the first patient-centred, shared decision-making model of deprescribing based on empirical evidence. This model will benefit the NHS, patients with frailty, and all patients with polypharmacy.

HSCIC 2014. Health Survey for England - 2013. Health & Social Care Information Centre.

LUYMES, C. H., VAN DER KLEIJ, R. M., POORTVLIET, R. K., DE RUIJTER, W., REIS, R. & NUMANS, M. E. 2016. Deprescribing Potentially Inappropriate Preventive Cardiovascular Medication: Barriers and Enablers for Patients and General Practitioners. Ann Pharmacother, 50, 446-54.

REEVE, E., TO, J., HENDRIX, I., SHAKIB, S., ROBERTS, M. S. & WIESE, M. D. 2013. Patient barriers to and enablers of deprescribing: A systematic review. Drugs and Aging, 30, 793-807.

^a University of Bradford

^b University of Leeds